U.S. Medicaid rule ends coverage of hormones and surgeries for gender-related care for minors

On October 13, 2026, a rule will take effect in the United States that leaves little room for interpretation: the federal health insurance programs Medicaid and the Children’s Health Insurance Program (CHIP) will no longer cover puberty blockers, cross-sex hormones or surgeries when they are used for gender transition in minors. The rule, adopted by the Centers for Medicare & Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS), was published in the Federal Register on August 13, 2026. Since then, reactions have ranged from relief to outrage — and the first lawsuits have already been filed.

What exactly the rule changes

The rule is narrow but firmly worded. For Medicaid beneficiaries under 18 and CHIP participants under 19, federal funding for puberty blockers, hormone therapy and surgical procedures specifically intended for gender transition will end. Young people who are already taking hormones will be covered by a transitional arrangement: they will retain federal coverage for a maximum of six months, solely for a medically supervised tapering process. Treatments for intersex conditions (DSD), other medical indications and care for complications remain unaffected, as does mental health care that Medicaid and CHIP already cover. It is also important to note what the rule does not do: it does not prohibit providers or clinics from offering these treatments. A state that wants to use its own funds may continue to do so — only the federal contribution is withdrawn. For poorer families in states that rely heavily on federal matching funds, that difference will often amount in practice to the difference between having access and not having access.

Legal opposition: who is challenging the rule and why

At the beginning of October 2026, four low-income families in New Hampshire, represented by the ACLU of New Hampshire, filed a lawsuit against the Trump administration. Their argument is that their children are losing access to care for which no alternative is available, while the families themselves cannot afford to pay for it. The rule is also controversial under administrative law. In mid-August, analysts at the health news outlet STAT News had already pointed out that the legal basis on which CMS relies — the claim that gender-transition care for minors is not demonstrably “medically necessary” — will itself become the subject of litigation, because the law normally gives CMS little room to categorically exclude entire treatment categories in this way. The federal court therefore will not primarily be deciding whether puberty blockers are “good” or “bad,” but whether an agency such as CMS is actually allowed to make this decision without congressional involvement.

The heart of the dispute: how strong is the evidence?

Underlying the legal battle is a substantive question that has long been debated outside the United States as well: how robust is the evidence for puberty blockers, hormones and surgery in minors with gender dysphoria? The United Kingdom’s Cass Review concluded that the evidence base is “remarkably weak,” Sweden tightened its guidelines following the SBU report, and Finland and Norway have also been moving toward a more cautious approach for years. CMS cites similar concerns in its explanation of the rule. Yet not every argument made by the current administration is equally robust: in late September, NPR examined a separate HHS report on “gender ideology” and found that it had not been peer-reviewed, relied on figures from an activist advocacy organization and omitted important context. The fact that a government is simultaneously circulating a poorly substantiated ideological report and introducing a stricter funding rule that does rely on recognized evidence reviews shows that being “critical of the evidence base” in the United States has by now become just as much a political weapon as the affirmative model it criticizes. For anyone seeking to follow the issue on the facts, that distinction — between a substantiated evidence review and a political report that happens to point in the same direction — is precisely what matters.

What this means for the Netherlands

A federal reimbursement rule in the United States does not change the Dutch healthcare system. But the underlying debate is certainly cross-border: here too, the development of the Dutch quality standard for transgender care came under criticism because health insurers were not involved at the time and “informed consent” was given its own, later interpretation. The U.S. episode is also not an isolated event: earlier this year, the Trump administration put forward Heidi Overton, an outspoken critic of gender-affirming care, as a candidate for FDA commissioner, and in Texas, following a ten-million-dollar settlement, the first U.S. detransition clinic opened. The Medicaid rule is part of that same broader shift in policy — with one important difference: this is not about a lawsuit or an appointment, but about who will still have access to care, regardless of what one thinks of that care.

Sources

• AJMC, "CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care", August 2026. ajmc.com
• STAT News, "How will legal challenges fare against CMS rule on gender-affirming care?", August 14, 2026. statnews.com
• ACLU New Hampshire, press release "New Hampshire families sue to stop the Trump administration from cutting off medical care for transgender youth on Medicaid", October 2026. aclu-nh.org
• NPR, "What's behind HHS claims that gender-affirming care 'may' radicalize", September 30, 2026. npr.org

Edward Jansen

Genderinfo.nl